Polyendocrine Metabolic Ovarian Syndrome (PMOS) is the new name for the condition previously known as Polycystic Ovary Syndrome (PCOS), which impacts 1 in 8, or more than 170 million women worldwide.
The new name came from the largest global engagement in a name change process with 22,000 survey responses and multiple workshops including women with lived experience and health professionals, alongside 56 patient organisations and societies across the world, including IFFS.
For too long, PCOS reduced a complex, long term hormonal or endocrine disorder to a misunderstanding about ‘cysts’ and a focus on ovaries. This contributed to missed diagnoses and inadequate treatment.
Women with the condition were the biggest drivers to change the name through their voices and advocacy. Doctors and health professionals strongly supported the change.
The new name PMOS, accurately reflects the condition and its symptoms. The name change will facilitate greater awareness to improve care and outcomes.
Resources in multiple languages are available: https://bit.ly/3V85nPJ